CTOs on the Move

Meridian Heights Afc

www.hiawathabehavioral.org

 
Meridian Heights Afc is a Sault Sainte Marie, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Tecan

Tecan Group Ltd. is a Swiss company providing laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics for pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories.

Capio Partners

Capio Partners provides revenue cycle solutions for some of the nation`s leading healthcare providers and hospital systems, converting uncollected receivables into cash. As the healthcare industry moves towards purchasing solutions, Capio Partners offers leadership, knowledge, innovation, and unsurpassed results to help you maximize revenue and minimize risk.

Lifeblood Mid South Regional Blood Center

Lifeblood opens the East Donor Center on Estate Drive. In 1954, another proposal to establish a blood center in Memphis was rejected for the same reason-it was too costly. Finally in 1962, the Committee on Blood Bank Operation of the Memphis and Shelby

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.